

29 June 2021

Cizzle Biotechnology Holdings Plc
("Cizzle Biotechnology" or the "Company")

Result of GM

Cizzle Biotechnology, a UK based developer of a blood test for the early detection of a majority of the different forms of lung cancer, announces that at the General Meeting ("GM") of the Company held earlier today, all resolutions were voted on by a poll and were passed.

The votes cast in respect of the resolutions were as follows:

Resolution	For		Against		Votes withheld
	Total votes	%	Total votes	%	
1. That the Annual Report and Accounts for the year ended 31 December 2020 be received	8,175,004	100.00%	2	0.00%	0
2. That PKF Littlejohn LLP be appointed as the Company's auditor	8,175,004	100.00%	2	0.00%	0
3. That the directors be authorised to agree the remuneration of the auditor	8,102,609	100.00%	2	0.00%	72,395

Enquiries:

Cizzle Biotechnology Holdings plc
Allan Syms (Executive Chairman)

Via IFC Advisory

Allenby Capital Limited
John Depasquale
Alex Brearley

+44(0) 20 33285656

Novum Securities Limited
Colin Rowbury
Jon Bellis

+44(0) 20 7399 9400

IFC Advisory Limited

Tim Metcalfe

Florence Chandler

+44(0) 20 3934 6630

About the Company

Cizzle Biotechnology is developing a blood test for the early detection of a majority of the different forms of lung cancer. Cizzle Biotechnology is a spin-out from the University of York, founded in 2006 around the work of Professor Coverley and colleagues. Its proof-of-concept prototype test is based on the ability to detect a stable plasma biomarker, a variant of CIZ1 known as CIZ1B. CIZ1 is a naturally occurring cell nuclear protein involved in DNA replication, and the targeted CIZ1B variant is highly correlated with early stage lung cancer.

For more information please see <https://cizzlebiotechnology.com>

You can also follow the Company through its twitter account @CizzlePlc and on LinkedIn.